
Prime Stock alert: Moving this pharma stock to a HOLD
Recent announcements relating to ownership change in this pharma stock prompt us to move this stock from a ‘BUY’ to a ‘HOLD’.

Recent announcements relating to ownership change in this pharma stock prompt us to move this stock from a ‘BUY’ to a ‘HOLD’.

A report from Kotak Institutional Equities sparked a bout of selling in mid and small caps. Should you be concerned? Here is what we think.

We are adding this secured, listed NCD with attractive yields that compensate for the risk which is also mitigated by other factors.

As stocks across market caps have run up, we are taking a look at Prime Stocks with a special focus on valuations and are moving these two stocks to a ‘HOLD’.

Episode 08 of the Prime Podcast

Results update for 5 of our Prime Stocks.

While the Nifty 50 slipped into correction, it rebounded from key support levels. So how is the index likely to trend now?

It’s raining high-yield NCDs and this article gives you a framework to filter these to arrive at the best candidates for your portfolio.

This commodity stock is well placed to play the changing tide in the sector on account of its affordable valuations.

While this sector is currently in a consolidation zone, it’s a good time to begin loading up as factors for a recovery are starting to line up.

Understanding the tax change for life insurance policies brought about by Budget 2023 via the recent CBDT guideline.

This NCD has three tenors and yields offer a good spread over both government and AAA-rated corporate debt.
Hold On
You are being redirected to another page,